Komipharm International코미팜
041960 · KOSDAQ · ₩041960 · 코미팜
₩8,750▲ ₩70 (0.81%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 35.0% | 32.5% | 37.0% | 29.7% | 28.8% | 31.3% |
| Operating margin | 3.3% | 3.7% | 10.5% | −14.7% | −9.6% | −14.8% |
| Net margin | −4.9% | −13.7% | 22.3% | −9.3% | −16.4% | −12.4% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +1.1% | −10.7% | +37.8% | +7.2% | +11.0% | — |
| Operating income growth | −10.0% | −68.3% | +198.7% | −64.9% | +28.1% | — |
| Net income growth | +64.2% | −155.0% | +429.6% | +38.9% | −46.1% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −3.7% | −10.9% | 22.1% | −6.8% | −10.3% | −6.7% |
| Return on assets | −3.1% | −6.3% | 12.2% | −5.1% | −6.6% | −5.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 87.6% | 85.8% | 87.3% | 97.6% | 70.2% | 59.2% |
| Net debt to equity | 18.1% | 17.0% | 32.0% | 49.6% | 41.0% | 29.1% |
| Current ratio | 130.6% | 129.8% | 129.6% | 95.8% | 103.9% | 161.4% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Komipharm International / 코미팜 / 041960 / KRX:041960
Source: KRX statistical information